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The human gut is one of the most complex ecosystems, composed of 1013-1014 microorganisms which play an
important role in human health. In addition, some food products contain live bacteria which transit through our
gastrointestinal tract and could exert beneficial effects on our health (known as probiotic effect). Among the
numerous proposed health benefits attributed to commensal and probiotic bacteria, their capacity to interact with
the host immune system is now well demonstrated. Currently, the use of recombinant lactic acid bacteria to deliver
compounds of health interest is gaining importance as an extension of the probiotic concept. This review
summarizes some of the recent findings and perspectives in the study of the crosstalk of both commensal and
probiotic bacteria with the human host as well as the latest studies in recombinant commensal and probiotic
bacteria. Our aim is to highlight the potential roles of recombinant bacteria in this ecosystem.
Keywords: Bacteria-host crosstalk, Dysbiosis, Genetically modified microorganismsRelationship humans-bacteria: a history of
common benefits
The human gastrointestinal tract (GIT) is one of the
most complex ecosystems known. Its microbiota consists
of a large number of bacteria (10-fold more than the total
number of human cells) that shapes many important
physiological and metabolic processes as well as the
development of the immune system [1,2]. The advances
of molecular techniques have shown that the collective
adult human GIT microbiota is composed of up to
1000–1150 bacterial species [3,4]. The most frequently
found species are Gram-positive bacteria. The predomin-
ant species (46-58%) are those with low GC-content and
the Clostridium group is the most abundant in this com-
plex ecosystem [4]. Physiological conditions differ widely
in the human GIT leading to an individual gut micro-
biota [5]. Some studies suggest that the faecal microbiota
does not necessarily represent the bacteria inside the GIT
[6-8]. Additionally, the intestinal lumen microbiota differs* Correspondence: luis.bermudez@jouy.inra.fr
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reproduction in any medium, provided the orsignificantly from the one in the mucus layer and near the
epithelium due to the poor accessibility of the crypts
covered by mucins [9].
Despite its complexity, the faecal microbiota of adult
human individuals is unique and highly stable through
time [10]. Primocolonizing microorganisms appear in
the gut immediately after birth in an organized and life-
long process [11]. During the first year, after the initial
establishment of the intestinal microbiota, its compo-
sition is relatively simple and varies between individuals
[12]. After that, the main dominant groups of the adult
microbiota will be conserved between all individuals.
These groups are stable in spite of the great number of
factors that can affect them [13]. In contrast, at the
phylum level, the variation is higher between individuals
although people who are related tend to have similar
microbiota perhaps due to a shared environment and
genetic similarities [13].
This microecosystem, which is a direct consequence of
the mutualism between the host and its microbiota, is
fundamental for the maintenance of the homeostasis of a
healthy individual [5]. Commensal bacteria provide the
host with essential nutrients. They metabolize indigestibleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pathogens and contribute to the development of the in-
testinal architecture as well as stimulation of the immune
system among others [11]. Conversely, the host provides
the bacteria with nutrients and a stable environment [5]
(Figure 1). Both host and indigenous microorganisms
have then adapted to each other in a particular case of
microevolution to maintain the benefits that this mutua-
lism confers [2].
Probiotics: an additional bacterial advantage
for humans
Probiotics are defined as “live microorganisms which
when administered in adequate amounts confer a health
benefit on the host” [14]. This concept is based on the
observations made by Élie Metchnikoff in 1907 in which
the regular consumption of Lactic Acid Bacteria (LAB)
in fermented dairy products, such as yogurt, was asso-
ciated with enhanced health and longevity in many
people living in Bulgarian villages [15].Figure 1 Commensal bacteria cross talk with the host. Commensal bac
against opportunistic pathogens. They are involved in the development of
other hand, the host provides the bacteria with nutrients and a stable enviMost probiotics belong to LAB, but new species and
genera are being assessed for future use. Some other well-
known probiotics are Bifidobacterium sp., one strain of the
Gram-negative bacterium Escherichia coli Nissle 1917 and
the yeast Saccharomyces boulardii [16].
However, not all microorganisms are beneficial and
screenings in order to identify novel candidate probiotics
with immunomodulatory properties are frequently per-
formed [17]. In fact, a Dutch trial using a probiotic
preparation in patients with acute pancreatitis showed to
be harmful [18]. These negative results show how
important it is to choose the right protocol (indeed, the
main problem with this study was the bad idea to
administer massive quantitites of probiotics in very vul-
nerable patients) and to make a careful selection when
using probiotics in humans. Certainly, a supposed bene-
ficial effect of a specific strain cannot be extrapolated to
another strain even within to the same species [19,20].
Modulation of host immunity and promotion of host
defense are the most commonly supported benefits ofteria supply the host with essential nutrients and defend the host
the intestinal architecture and immunomodulatory processes. On the
ronment.
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be considered probiotic (i.e. bacteria or yeast), the
following criteria need to be fulfilled: i) it should have a
clear beneficial effect on the host, ii) it should be non-
pathogenic, iii) it should be able to survive transit
through the GIT and iv) a large number of viable bacteria
must be able to survive prolonged periods (i.e. upon
storage) [21].
What happens if homeostasis is broken?
The term dysbiosis refers to microbial imbalances on or
within the body. When homeostasis (balanced microbial
ecosystem) is broken, different subdominant opportunis-
tic bacteria can grow leading to a situation of illness.
Additionally, when commensal bacteria are depleted, an
abnormal health situation can be triggered due to a lack
of the benefits these bacteria provide rather than the
overgrowth of pathobionts.






diabeThe term dysbiosis has been related to many
different kinds of pathologies although it is not clear
whether the imbalance of microbiota is a cause or a
consequence of the illness. The clearest correlation
between dysbiosis and disease has been found with
inflammatory bowel diseases (IBD) where the
proportion of Firmicutes, in particular
Faecalibacterium prausnitzii, was found to be low in
patients that exhibited endoscopic recurrence
6 months after surgery [22,23]. IBD, including
Crohn’s disease (CD) and ulcerative colitis (UC), are
characterized by an abnormal activation of the
immune system associated with the gut, resulting in
a chronic inflammation of the digestive system.
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↑ Bacteroidesinvolved in IBD such as genetic components [24,25],
immunological disorders [26], environmental factors
[27,28], pathogens [29,30], and microbiota [10].
Faecal analyses have shown a quantitative and
qualitative reduction in the representation of the
Firmicutes phylum, mostly the clostridial cluster IV
members in CD patients while low numbers of total
lactobacilli have been reported in UC members
[31,32], although no correlation was found between
F. prausnitzii abundance and the severity of CD [33].
Even if the composition of the human microbiota is
different in each individual, changes in phylogenic
distribution have also been specifically found in
obese and diabetic individuals versus normal ones
[34,35] (Table 1). The importance of the human
microbiota has been demonstrated in the hygiene
hypothesis, defined in 1989 by Strachan [36] who
postulated that low exposure to infectious agents in
early life explains the increased numbers of people
suffering from allergies and asthma in developed
countries. This hypothesis suggests that a
well-balanced human microbiota is a factor that
protects from such pathologies [37,38].
Some microbial activities have shown relevance to
health and disease. Following this line of thought,
the production of short chain fatty acids (SCFA)
such as butyrate has been proposed to protect
against different illnesses (Table 2).
b) Probiotics to restore dysbiosis
As we have seen before, dysbiosis are involved in a
great variety of different illnesses. Considering this
fact, the administration of beneficial microorganisms
to restore the normal ecosystem is a strategy to
improve the health status of the patient and/or to
prevent a normal healthy individual from acquiringtes
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RNA sequencing Faecal [44]






Table 2 Benefical effects of short chain fatty accids (SCFA)
SCFA Model Effect Reference
Butyrate Tumorigenesis in rat colon and Human colonic cells Inhibit the genotoxic activity of nitrosamides
and hydrogen peroxide
[47]
Human adenocarcinoma R6/C2 and AA/C1 cells and
carcionoma PC/JW/F1 cells
Induce apoptosis [48]
Human intestinal primary epithelial cells (HIPEC), HT-29
and Caco-2 cells
Immunoregulatory effects [49]
Humans with distal ulcerative colitis Improves UC symthoms [50]
Butyrate/acetate/propionate Humans with diversion colitis Improves the macroscopic and histological
signs of inflammation
[51]
Propionate HT-29 cells Anti-proliferative effects [52]
Madin-Darby bovine kidney epithelial cells (MDBK) [53]
Acetate E. coli O157:H7 infection Protection [54]
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of the use of probiotics as therapeutics against
traveler’s diarrhea, irritable bowel syndrome (IBS),
IBD, lactose intolerance, peptic ulcers, allergy and
autoimmune disorders among others [55-60]. For
instance, it has been suggested that colonization of
the GIT with Bifidobacteria properly shapes gut
microbiota, induces oral tolerance and decreases the
frequency of allergic disorders [61]. For lactobacilli,
a clinical study demonstrates that perinatal
administration of a probiotic strain of Lactobacillus
rhamnosus GG (LGG) reduces the development of
atopic eczema in children [61-64]. This effect may
be due to the anti-inflammatory properties of this
probiotic bacterium. Consumption of LGG by
children with atopic dermatitis has been reported to
enhance the production of the anti-inflammatory
cytokine IL-10 [65]. Other studies have
demonstrated that oral administration of L. casei
Shirota strain to mice inhibited specific IgE
production [66] while Abrahamsson et al. [67] have
observed in a double-blind, randomized, placebo-
controlled trial that infants treated with L. reuteri
ATCC 55730 strain had less IgE-associated eczema.
As mentioned above, when the equilibrium of the
microbiota is disturbed, the bacterial ecosystem is
thought to contribute to several intestinal diseases
such as IBD. In fact, gut microbiota metabolize
nutrients, produce vitamins and degrade toxic
products (such as: carcinogens, food additives, bile
salts, and cholesterol, among others) [68,69], where
the importance and interest in modulate microbiota
with probiotic products. Results from animal models
and human clinical trials have confirmed various
therapeutic effects of selected strains of probiotics in
IBD [56,70]. For instance, L. casei BL23 strain has
shown anti-inflammatory effects in a murine DSS-
induced colitis model [71] and some other probioticstrains (eg. VSL#3, LGG, BIFICO, E. coli Nissle) have
shown effects in human patients with pouchitis, UC
and CD [72]. Additionally, the modulatory effect of
Lactobacillus acidophilus in intestinal pain due to
the induction of opioid and cannabinoid receptors
has been reported in rats [73]. This fact highlights
the use of probiotics in other intestinal disorders
such as such as IBS, characterized by chronic
abdominal pain, discomfort, bloating and alteration
of bowel habits. In this sense, in the last years, many
studies confirm the overall positive results of
probiotics in human IBS patients using different
bacteria such as: Lactobacillus spp., Bifidobacterium
and Streptococcus among others [74].
From this perspective, the use of probiotics has been
expanded in the last few years, with a great number
of probiotic products in our supermarkets and
pharmacies. However, the knowledge of their
mechanisms of action remains largely unknown.New prospects of commensal and probiotic
bacteria: genetically modified microorganisms
a) Strategies to deliver therapeutic molecules.
Since probiotic therapy is mainly focused on
restoring the normal balance of the intestinal
ecosystem, we can deduce that the use of
commensal bacteria as probiotics is the natural way
to get rid of dysbiosis within the GIT. Furthermore,
they represent potential live delivery vectors for
target compounds (Figure 2). The use of live delivery
vectors, such as food-grade LAB, at the mucosal
level has been widely described before [75-79]. They
are based on the use of recombinant bacteria
producing the heterologous molecule of interest
in vivo and their use is mainly related to vaccines.
This is due to the fact that genetically engineered
bacteria or viruses (used as carriers) producing
Figure 2 Extension of the commensals-probiotics hypothesis. The development of a genetically modified commensal (or probiotic) could
reach all the beneficial properties found in a commensal bacterium joint to the probiotic effects due to the ability to deliver molecules to the
gastrointestinal tract (GIT).
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immunogenicity of otherwise weakly immunogenic
antigens. In addition, such live bacterial vectors have
the additional advantage (compared to viruses) of
having a genome able to harbor many heterologous
genes, in contrast to viruses where the capacity to
encapsulate foreign DNA is limited. This research
field comes from exploring novel effective strategies
to deliver therapeutic molecules to the mucosal
tissues in order to avoid degradation and promote
uptake of the antigen in situ (ie. in the GIT), and
stimulate adaptive immune responses rather than
the tolerogenic immune responses that are observed
in feeding studies with soluble antigens [80]. Besides
the enhancement of the potency and specificity of
mucosal delivery of therapeutic molecules, the use of
mucosal routes reduces potential side effects
observed in systemic ones.
In principle, two types of bacterial vectors can be
used to deliver compounds at the mucosal level:
attenuated pathogens and non-pathogenic bacteria.
Gram-positive commensal or food-grade bacteria
constitute attractive good alternatives to pathogenic
bacteria [79,81]. Particularly, the food-grade LAB are
attractive candidates because they have been used
for centuries in the fermentation and preservation of
food, and are considered to be safe organisms with a
GRAS (Generally Recognized As Safe) status. Onemajor advantage of LAB as delivery vectors for
vaccines purposes is their potential to elicit both
antigen-specific immune responses at mucosal
surfaces and effective systemic immune responses.
Indeed, some studies have successfully shown that
candidate LAB vaccines elicited antigen-specific IgA
responses in feces, saliva or bronchoalveolar and
intestinal lavage fluids, as well as antigen-specific
IgA-secreting cells in the lungs and mesenteric
lymph nodes [82-94].
These studies with encouraging results confirm the
potential use of LAB as live vectors for mucosal
immunization and/or therapy. In this context, the
model LAB species, Lactococcus lactis, has been
used for the heterologous expression of therapeutic
proteins such as: antigens, cytokines and enzymes.
Thus, the resulting recombinant lactococci strains
have been successfully tested for their prophylactic
and therapeutic effects in many animal models
such as: Human Papillomavirus type-16
(HPV-16)-induced tumors in mice [83,88], bovine
β-lactoglobulin (BLG)-allergic reaction in mice
[95,96] and body weight and food consumption in
obese mice [85,97].
b) Use of recombinant LAB and commensals in IBD.
Modulation of the mucosal immune system has
been demonstrated in IBD. The currently
used therapies to treat IBD are based on
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immunosuppressives [98]. Immunomodulatory
molecules have been efficient in the control of
inflammation and in the remission of the episodes of
the illness. The use of LAB to prevent and treat
colitis was performed with a recombinant L. lactis
strain producing and delivering IL-10, an
anti-inflammatory cytokine, in situ in different
mouse models [99]. Daily mucosal administration of
recombinant L. lactis secreting IL-10 led to a 50%
decrease of the colitis induced by the administration
of dextran sodium sulfate (DSS) in mice. This
beneficial effect was dependent on the in situ
secretion of IL-10 by the live lactococci. The
rationale in using recombinant L. lactis for a local
delivery of IL-10 in IBD is due to the large number
of scientific studies proving that the topical
treatment with this cytokine has clinic benefits [100]
although systemic IL-10 administration in Crohn’s
disease patients has been associated with
considerable side effects which are partly due
to the fact that systemic IL-10 induces the pro-
inflammatory cytokine IFN-γ [101-103]. To address
the safety issues in using genetically modified
organisms in humans, the gene encoding the L.
lactis thymidylate synthase (thyA) was replaced by
the gene of the human IL-10 (hIL-10) to generate
one L. lactis strain auxotrophic for thymidine or
thymine [104]. The viability and contention of this
strain was validated in vivo in a swine model [104].
Additionally, a small Phase I clinical study in
patients with CD using the thyA-/hIL-10+ strain
was recently conducted. This study not only showed
that the contention strategy is effective, but also that
the mucosal expression of IL-10 by L. lactis is
feasible in humans [105]. However, a phase IIA trial
was performed which revealed that, although safety,
tolerability, environmental containment and
assessment of biomarkers associated with the strains
have been achieved, no statistically significant
difference has been found versus placebo in terms of
beneficial effects (press release published in 2009).
Due to these results, the necessity to optimize the
LAB delivery strategy (new strains, different
expression systems and different nature of the
delivered molecules) is a requirement to reach a
clear demonstration of their efficacy in human
clinical trials, leading to their better acceptance
[76-78,106-109]. The delivery of immunosuppressive
cytokines by other bacteria has also been tested. The
probiotic potential of IL-10-expressing E. coli Nissle
1917 has been outlined in a mouse model of IBD
[110]. The use of LAB to produce Trefoil Factors
(TFF) at the mucosal level to treat IBD has alsobeen studied. TFF are a class of nonmitogenic
peptides that play important roles in the protection
and repair of the intestinal epithelium [111]. These
peptides are known because of their strong
protective effects and for repairing the mucosa after
damage. For this reason, they are interesting
molecules to potentially treat IBD. However, when
they are administered by an oral route, they adhere
to the gut mucosa and are absorbed at the intestinal
level. Interestingly, intragastric administration of
recombinant L. lactis secreting TFF leads to the
expression of the active peptides in the colon and
prevents and repairs the damage due to the acute
colitis induced by DSS [112]. Another strategy to
treat colitis was also based on the use of
recombinant L. lactis secreting the LcrV antigen, an
anti-inflammatory protein produced by Yersinia
pseudotuberculosis to escape the immune response
of the host. The therapeutic and protective potential
of this strain was evaluated using two colitis murine
models: DSS and trinitrobenzene sulfonic acid
(TNBS) [113]. Still, another strategy to treat IBD is
the use of antioxidant enzymes. It is well established
that GIT inflammation is associated with an influx
of neutrophils and macrophages and with the
production of inflammatory mediators such as:
proteases, cytokines and reactive oxygen species
(ROS) [114]. ROS include the superoxide radical
(O2°-), hydrogen peroxide (H2O2), and the hydroxyl
radical (·OH). Their reactivity toward lipids, proteins
and DNA causes both cytotoxic and mutagenic
cellular damages [115]. To detoxify ROS, cells have
evolved protective mechanisms via antioxidant
enzymes such as superoxide dismutases (SOD) and
catalases (CAT) which degrade O2°
- and H2O2
respectively, and thus prevent the formation of·OH
[116]. In this context, different studies have shown
that recombinant strains of Lactobacillus spp.
expressing either SOD or CAT can reduce
inflammation in mouse models [71,117-119]. In
some cases, the anti-inflammatory mechanism of
these recombinant strains has been elucidated and
linked to the inhibition of neutrophil recruitment
[117]. The mucosal expression of elafin, a natural
protease inhibitor expressed in healthy intestinal
mucosa, is diminished in patients with IBD.
Recently, LAB secreting elafin have been tested in
chronic and acute colitis models and the inflamed
epithelium was protected from increased intestinal
permeability and from the release of cytokines and
chemokines by LAB secreting elafin [120].
In addition to these recombinant probiotic strains,
mutants in specific genes encoding potential
probiotic functions (mucal adhesion factors,
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etc.) have been engineered to compare their
biological effects with that of their wild-type
counterparts. In 2005, Grangette et al. [121] has
provided an illustration of this approach by
constructing a mutant of Lactobacillus plantarum
impaired in its capacity to incorporate D-alanine in
teichoic acids (Dlt- mutant) [121]. Strikingly, when
tested in vivo, the Dlt- mutant proved to be more
protective in a mouse model of colitis than the wild-
type strain. Furthermore, the use of lipoteichoic acid
(LTA)-deficient L. acidophilus in in vitro analysis
enhances IL-10 production by dendritic cells and
macrophages and downregulates IL-12 and TNF-α
[122]. This strain is also able to significantly protect
dextran sulfate sodium and CD4+CD45RBhigh
T cell-induced colitis in mice [123] and to normalize
innate and adaptative pathogenic immune responses
in established colonic polyps causing cancer
regression [124]. However, no protective effects have
been found in LTA-induced pro-inflammatory
signals and subsequent colitis [125]. Altogether, with
the possibility to express different factors such as
ScFv antibodies, host targeting molecules and
immunomodulators in LAB, more applications and
progress towards studies in humans should be
performed in a next future.
The next step in this field seems to choose new
delivery bacteria. As mentioned above, L. lactis is the
most widely used LAB in the production of
heterologous proteins and is considered as the model
LAB and live delivery vector model [75]. Despite all
the advantages mentioned above, this bacterium has a
short survival time (~24 hours) in the human GIT
leading thus to a reduced time of action. In contrast,
other probiotic bacteria which could be natural
colonizers of the GIT, could combine their intrinsic
probiotic effects to the probiotic effects conferred by
the heterologous delivered protein. The most
achieved project in this field is the one based on the
use of the commensal Bacteroides ovatus [126]
Indeed, Hamady et al. [127] chose this bacterium for
the in vivo delivery of proteins for its ability to
colonize the colon and its xylan utilisation properties.
They were able to develop a xylan-regulated delivery
of i) human keratynocyte growth factor-2 to the
inflamed colon [128] and ii) the human TGF-b1 to
treat colitis in mice [129]. These promising results
confirm the potential of the use of recombinant
commensal for in vivo delivery.Conclusions and future research
We can conclude that current probiotic research en-
courages the search and characterization of gut bacteriaas a model for finding new natural or engineered pro-
biotic strains to be used to restore the normal balance of
the human gut ecosystem.
The fact that commensal and probiotic bacteria inter-
act with the host immune system is now well accepted
and illustrated by in vitro and in vivo experiments.
However, the current knowledge of the molecular mecha-
nisms involved in this cross-talk remain poorly under-
stood. Although some mechanisms and active compounds
have been identified in a few commensal or probiotic
strains [130], and taking into account that the human GIT
is composed of 1013-1014 microorganisms, it is necessary
to explore profoundly this research area and in particular
to elucidate the exact role of bacterial compounds in
homeostasis and immune response.
As for the use of genetically modified commensal and
probiotic bacteria in humans, it is certain that most of
the studies being done are Proof-of-Concept. However,
although some researchers have claimed that genetically
modified probiotics should be banned [131], the data
obtained in the phase I clinical trial with the recom-
binant strain of L. lactis secreting IL-10 (see above in
the text) showed that the containment strategy (ie. re-
lease of such genetically modified organisms into na-
ture) used to construct the strain [104] was not only
safe and effective but also that mucosal delivery of IL-
10 by a genetically modified LAB is feasible in humans
[105].
In conclusion, it is clear that the analysis of the impact
of commensals and probiotics on the host immune sys-
tem has entered a new and fascinating phase of research.
This new area offers us new knowledge that can be
exploited to develop new approaches to modulate host
immunity for protection against infectious diseases or
for immunotherapy.
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